Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SynAct Pharma AB ( (SE:SYNACT) ) has provided an update.
SynAct Pharma AB announced that its top leadership, including the CEO, CSO, CBO, and Chairman of the Board, have collectively acquired 12,028 shares in the company on Nasdaq Stockholm, signaling internal confidence in the firm’s prospects. Management highlighted that recruitment in the company’s lead program in rheumatoid arthritis is nearing completion and that it is preparing to initiate a clinical trial in viral infection, underscoring an active late-stage pipeline and setting expectations for a data-rich 2026 that could be significant for investors and the company’s positioning within inflammatory disease therapeutics.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm that focuses on treating inflammatory conditions through resolution therapy by selectively activating the melanocortin system. Its portfolio includes oral and injectable selective melanocortin agonists aimed at promoting anti-inflammatory and inflammation-resolving activity to restore immune balance in patients suffering from inflammatory diseases.
YTD Price Performance: 127.55%
Average Trading Volume: 142,243
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.09B
Find detailed analytics on SYNACT stock on TipRanks’ Stock Analysis page.